trending Market Intelligence /marketintelligence/en/news-insights/trending/gPXRlqtd7L_6b3XctAgH9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Boston Scientific Q3 profit rose 13.4% YOY; outlook revised

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Boston Scientific Q3 profit rose 13.4% YOY; outlook revised

Boston Scientific Corp. said its adjusted net income for the third quarter grew 13.4% year over year and revised its full-year guidance.

The Marlborough, Mass.-based healthcare equipment company's third-quarter adjusted net income came in at $550 million, or 39 cents per share, up from $485 million, or 35 cents per share, a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was 38 cents.

Net sales for the quarter increased 13.1% year over year to $2.71 billion from $2.39 billion. Research and development expenses were $306 million, up from $289 million in the year-ago quarter.

On a GAAP basis, net income amounted to $126 million, or 9 cents per share, a 70.8% decline from $432 million, or 31 cents per share, in 2018.

For the first nine months of 2019, Boston Scientific booked adjusted net income of $1.59 billion, or $1.13 per share, up 5.4% from $1.51 billion, or $1.08 per share, in 2018.

Nine-month GAAP net income totaled $704 million, or 50 cents per share, down from $1.29 billion, or 92 cents per share, in the year-ago period.

In addition, net sales for the nine months ended Sept. 30 came in at $7.83 billion, an increase from $7.26 billion, in the same period of 2018.

Boston Scientific updated its adjusted EPS guidance for the full year to a range of $1.55 to $1.58 from the prior outlook of $1.54 to $1.58. The company also further lowered its GAAP EPS outlook at between 72 cents and 75 cents from its previous estimate of 94 cents to 98 cents.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $1.55.